Effects of Combination Lipid Therapy on Coronary Stenosis Progression and Clinical Cardiovascular Events in Coronary Disease Patients With Metabolic Syndrome: A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS)

American Journal of Cardiology

Volumn 104, Issue 11, 2009, Pages 1457-1464

  Zhao, Xue Qiao ^a   Krasuski, Richard A ^c   Baer, Jefferson ^d   Whitney, Edwin J ^e   Neradilek, Blazej ^b   Chait, Alan ^a   Marcovina, Santica ^a   Albers, John J ^a   Brown, B Greg ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Mountain Whisper Light Statistical Consulting   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d EMORY UNIVERSITY   (United States)

^e Heart and Vascular Institute of Texas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MILITARY PERSONNEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 71649101609     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.07.035     Document Type: Article

References (23)

1. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., and Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
2. Brown B.G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., and Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
3. Whitney E.J., Krasuski R.A., Personius B.E., Michalek J.E., Maranian A.M., Kolasa M.W., Monick E., Brown B.G., and Gotto Jr. A.M. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005) 95-104
4. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
5. Robins S.J., Rubins H.B., Faas F.H., Schaefer E.J., Elam M.B., Anderson J.W., Collins D., and Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 26 (2003) 1513-1517
6. Friedman L.M., Furberg C.D., and DeMets D.L. Fundamentals of Clinical Trials. 3rd Ed. (1998), Springer, New York 301-303
7. Breslow N.E., and Day N.E. Statistical Methods in Cancer Research, Volume I (1980), International Agency for Research on Cancer, Lyon, France 29-30
8. Raghunathan T.E., Lepkowski J.M., Van Hoewyk J., and Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of Regression models. Surv Methodol 27 (2001) 85-95
9. Little R.J.A., and Rubin D.B. Statistical Analysis with Missing Data. 2nd Ed. (2002), John Wiley and Sons, Hoboken, NJ
10. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., Taskinen M.R., and Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
11. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., and Salonen J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
12. Davies M.J., Richardson P.D., Woolf N., Katz D.R., and Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 69 (1993) 377-381
13. Buchwald H., Matts J.P., Fitch L.L., Campos C.T., Sanmarco M.E., Amplatz K., Castaneda-Zuniga W.R., Hunter D.W., Pearce M.B., and Bissett J.K. Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. JAMA 268 (1992) 1429-1433
14. Waters D., Craven T.E., and Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 87 (1993) 1067-1075
15. Hulthe J., Bokemark L., Wikstrand J., and Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 20 (2000) 2140-2147
16. Jin F.-Y., Kamanna V.S., and Kashyap M.L. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 17 (1997) 2020-2028
17. Kamanna V.S., and Kashyap M.L. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2 (2000) 36-46
18. Canner P.L., and Halperin M. Implications of findings in the coronary drug project for secondary prevention trials in coronary heart disease. The coronary drug project research group. Circulation 63 (1981) 1342-1350
19. Canner P.L., Furberg C.D., and McGovern M.E. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction. Am J Cardiol 97 (2006) 477-479
20. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs Jr. D.R., Bangdiwala S., and Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
21. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith Jr. S.C., Spertus J.A., Costa F., American Heart Association; National Heart, Lung, and and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005) 2735-2752
22. Brown B.G., Stukovsky K.H., and Zhao X.Q. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 17 (2006) 631-636
23. Nicholls S.J., Tuzcu E.M., Sipahi I., Grasso A.W., Schoenhagen P., Hu T., Wolski K., Crowe T., Desai M.Y., Hazen S.L., Kapadia S.R., and Nissen S.E. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508